Unfortunately, preclinical studies in PDA patients have been unsuccessful so far because neither anti-CTLA4 nor anti-PD1 mAb treatments showed beneficial effects for survival.7 It suggests that an upstream molecule regulating anti-tumor T-cell responses could be considered as the clinical target. The gene discussed is CTLA4; the disease is neoplasm.